Literature DB >> 22177954

Oleanane triterpenoid CDDO-Me inhibits Akt activity without affecting PDK1 kinase or PP2A phosphatase activity in cancer cells.

Yongbo Liu1, Xiaohua Gao, Dorrah Deeb, Subhash C Gautam.   

Abstract

Our previous studies have shown that methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (CDDO-Me), a oleanane synthetic triterpenoid induces apoptosis in prostate cancer cells by inhibiting the Akt/NF-κB/mTOR signaling cascade; however, the mechanism by which CDDO-Me inhibits Akt/NF-κB/mTOR signaling has remained undetermined. Present studies show that Akt plays a critical role in the response of prostate cancer cells to CDDO-Me. Silencing of Akt sensitized PC-3 cells to CDDO-Me, whereas its overexpression rendered them resistant to CDDO-Me. Evaluation of the effect of CDDO-Me on Akt which lies upstream of NF-κB and mTOR showed that CDDO-Me directly inhibits the Akt kinase activity in cell-free kinase activity assay and in vivo without modulating the activity of PDK1, the upstream kinase that phosphorylates and activates Akt. The inhibition of Akt activity resulted in inhibition of phosphorylation/inactivation of proapoptotic procaspase-9, Bad and Foxo3a. Further, inhibition of p-Akt by CDDO-Me was not attributable to an increase in the activity of protein phosphatase 2A (PP2A) or PH domain/leucine-rich repeat protein phosphatase1 (PHLPP1) both of which dephosphorylate p-Akt. These findings show that Akt is a direct target of CDDO-Me in the Akt/NF-κB/mTOR prosurvival signaling axis.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22177954      PMCID: PMC3264055          DOI: 10.1016/j.bbrc.2011.12.007

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  23 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

2.  Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia.

Authors:  Marina Konopleva; Twee Tsao; Peter Ruvolo; Irina Stiouf; Zeev Estrov; Clinton E Leysath; Shourong Zhao; David Harris; Shirong Chang; C Ellen Jackson; Mark Munsell; Nanjoo Suh; Gordon Gribble; Tadashi Honda; W Stratford May; Michael B Sporn; Michael Andreeff
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

3.  The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells.

Authors:  M Konopleva; R Contractor; S M Kurinna; W Chen; M Andreeff; P P Ruvolo
Journal:  Leukemia       Date:  2005-08       Impact factor: 11.528

4.  The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells.

Authors:  Karen Liby; Nga Voong; Charlotte R Williams; Renee Risingsong; Darlene B Royce; Tadashi Honda; Gordon W Gribble; Michael B Sporn; John J Letterio
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

5.  Synthetic triterpenoids attenuate cytotoxic retinal injury: cross-talk between Nrf2 and PI3K/AKT signaling through inhibition of the lipid phosphatase PTEN.

Authors:  Ian Pitha-Rowe; Karen Liby; Darlene Royce; Michael Sporn
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-06-03       Impact factor: 4.799

6.  The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance.

Authors:  Takashi Ikeda; Michael Sporn; Tadashi Honda; Gordon W Gribble; Donald Kufe
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

7.  CDDO-me induces apoptosis and inhibits Akt, mTOR and NF-kappaB signaling proteins in prostate cancer cells.

Authors:  Dorrah Deeb; Xiaohua Gao; Scott A Dulchavsky; Subhash C Gautam
Journal:  Anticancer Res       Date:  2007 Sep-Oct       Impact factor: 2.480

8.  The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice.

Authors:  Karen Liby; Darlene B Royce; Charlotte R Williams; Renee Risingsong; Mark M Yore; Tadashi Honda; Gordon W Gribble; Ethan Dmitrovsky; Thomas A Sporn; Michael B Sporn
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

Review 9.  Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer.

Authors:  Karen T Liby; Mark M Yore; Michael B Sporn
Journal:  Nat Rev Cancer       Date:  2007-04-19       Impact factor: 60.716

10.  Prevention of Prostate Cancer with Oleanane Synthetic Triterpenoid CDDO-Me in the TRAMP Mouse Model of Prostate Cancer.

Authors:  Xiaohua Gao; Dorrah Deeb; Yongbo Liu; Ali S Arbab; George W Divine; Scott A Dulchavsky; Subhash C Gautam
Journal:  Cancers (Basel)       Date:  2011       Impact factor: 6.639

View more
  12 in total

1.  FOXO3a: A Potential Target in Prostate Cancer.

Authors:  Sanjeev Shukla
Journal:  Austin J Urol       Date:  2014

2.  Inhibition of cell proliferation and induction of apoptosis by oleanane triterpenoid (CDDO-Me) in pancreatic cancer cells is associated with the suppression of hTERT gene expression and its telomerase activity.

Authors:  Dorrah Deeb; Xiaohua Gao; Yongbo Liu; Sahn-Ho Kim; Kirit R Pindolia; Ali S Arbab; Subhash C Gautam
Journal:  Biochem Biophys Res Commun       Date:  2012-05-16       Impact factor: 3.575

Review 3.  Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: preclinical and clinical evidence.

Authors:  Muthu K Shanmugam; Xiaoyun Dai; Alan Prem Kumar; Benny K H Tan; Gautam Sethi; Anupam Bishayee
Journal:  Cancer Lett       Date:  2014-01-30       Impact factor: 8.679

Review 4.  Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease.

Authors:  Karen T Liby; Michael B Sporn
Journal:  Pharmacol Rev       Date:  2012-09-10       Impact factor: 25.468

5.  The role of stearoyl-coenzyme A desaturase 1 in clear cell renal cell carcinoma.

Authors:  Hui Wang; Yujian Zhang; Yongning Lu; Jiajia Song; Min Huang; Jin Zhang; Yiran Huang
Journal:  Tumour Biol       Date:  2015-07-31

6.  Nrf2 acts cell-autonomously in endothelium to regulate tip cell formation and vascular branching.

Authors:  Yanhong Wei; Junsong Gong; Rajesh K Thimmulappa; Beata Kosmider; Shyam Biswal; Elia J Duh
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-23       Impact factor: 11.205

7.  Nanoparticle delivery of CDDO-Me remodels the tumor microenvironment and enhances vaccine therapy for melanoma.

Authors:  Yan Zhao; Meirong Huo; Zhenghong Xu; Yuhua Wang; Leaf Huang
Journal:  Biomaterials       Date:  2015-08-01       Impact factor: 12.479

8.  Aristolochia manshuriensis Kom inhibits adipocyte differentiation by regulation of ERK1/2 and Akt pathway.

Authors:  Dong Hoon Kwak; Ji-Hye Lee; Taesoo Kim; Hyo Sun Ahn; Won-Kyung Cho; Hyunil Ha; Youn-Hwan Hwang; Jin Yeul Ma
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

9.  Inhibitory Effects of Hwangryunhaedok-Tang in 3T3-L1 Adipogenesis by Regulation of Raf/MEK1/ERK1/2 Pathway and PDK1/Akt Phosphorylation.

Authors:  Dong Hoon Kwak; Ji-Hye Lee; Dong-Gun Kim; Taesoo Kim; Kwang Jin Lee; Jin Yeul Ma
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-23       Impact factor: 2.629

10.  Telomerase reverse transcriptase (TERT) is a therapeutic target of oleanane triterpenoid CDDO-Me in prostate cancer.

Authors:  Yongbo Liu; Xiaohua Gao; Dorrah Deeb; Ali S Arbab; Subhash C Gautam
Journal:  Molecules       Date:  2012-12-11       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.